GlassScriptPhysician profile
Mark Anthony Naddaf
NPI 1124142500
$625.15
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $186 · 2021: $165 · 2022: $26.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $294.78 | 2019-2022 | |
| Abbvie INC. | $76.87 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.06 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $35.00 | 2019 | |
| Travere Therapeutics, INC. | $31.80 | 2019 | |
| Chiesi USA, INC. | $31.09 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $28.52 | 2019-2020 | |
| Qol Medical, LLC | $22.66 | 2020 | |
| Shire North American Group INC | $17.14 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $15.60 | 2019 | |
| Phadia US INC. | $14.63 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Naddaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.